FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092571714> ?p ?o ?g. }

• W3092571714 endingPage "2234" @default.
• W3092571714 startingPage "2220" @default.
• W3092571714 abstract "The aim of this study was to evaluate the effect of ticagrelor versus clopidogrel on left ventricular (LV) remodeling after reperfusion of ST-segment elevation myocardial infarction (STEMI) in humans. Animal studies have demonstrated that ticagrelor compared with clopidogrel better protects myocardium against reperfusion injury and improves remodeling after myocardial infarction. In this investigator-initiated, randomized, open-label, assessor-blinded trial performed at 10 centers in Korea, patients were enrolled if they had naive STEMI successfully treated with primary percutaneous coronary intervention (PCI) and at least 6-month planned duration of dual-antiplatelet treatment. The coprimary endpoints were LV remodeling index (LVRI) (a relative change of LV end-diastolic volume) measured on 3-dimensional echocardiography and N-terminal pro–B-type natriuretic peptide level at 6 months. Among initially enrolled patients with STEMI (n = 336), 139 in each group completed the study. LVRI at 6 months was numerically lower with ticagrelor versus clopidogrel (0.6 ± 18.6% vs. 4.5 ± 16.5%; p = 0.095). Ticagrelor significantly reduced the 6-month level of N-terminal pro–B-type natriuretic peptide (173 ± 141 pg/ml vs. 289 ± 585 pg/ml; p = 0.028). These differences were prominent in patients with pre-PCI TIMI (Thrombolysis In Myocardial Infarction) flow grade 0. By multivariate analysis, ticagrelor versus clopidogrel reduced the risk for positive LV remodeling (LVRI >0%) (odds ratio: 0.56; 95% confidence interval: 0.33 to 0.95; p = 0.030). The LV end-diastolic volume index remained unchanged during ticagrelor treatment (from 54.7 ± 12.2 to 54.2 ± 12.2 ml/m 2 ; p = 0.629), but this value increased over time during clopidogrel treatment (from 54.6 ± 11.3 to 56.4 ± 13.9 ml/m 2 ; p = 0.056) (difference −2.3 ml/m 2 ; 95% confidence interval: −4.8 to 0.2 ml/m 2 ; p = 0.073). Ticagrelor reduced LV end-systolic volume index (from 27.0 ± 8.5 to 24.7 ± 8.4 ml/m 2 ; p < 0.001), whereas no reduction was seen with clopidogrel (from 26.2 ± 8.9 to 25.6 ± 11.0 ml/m 2 ; p = 0.366) (difference −1.8 ml/m 2 ; 95% confidence interval: −3.5 to −0.1 ml/m 2 ; p = 0.040). Ticagrelor was superior to clopidogrel for LV remodeling after reperfusion of STEMI with primary PCI. (High Platelet Inhibition With Ticagrelor to Improve Left Ventricular Remodeling in Patients With ST Segment Elevation Myocardial Infarction [HEALING-AMI]; NCT02224534 )" @default.
• W3092571714 created "2020-10-15" @default.
• W3092571714 creator A5003862414 @default.
• W3092571714 creator A5005944401 @default.
• W3092571714 creator A5006217530 @default.
• W3092571714 creator A5013651361 @default.
• W3092571714 creator A5015711407 @default.
• W3092571714 creator A5016198765 @default.
• W3092571714 creator A5018245436 @default.
• W3092571714 creator A5020991381 @default.
• W3092571714 creator A5021399212 @default.
• W3092571714 creator A5022612041 @default.
• W3092571714 creator A5024380836 @default.
• W3092571714 creator A5024932707 @default.
• W3092571714 creator A5030301889 @default.
• W3092571714 creator A5034022066 @default.
• W3092571714 creator A5034107357 @default.
• W3092571714 creator A5035456738 @default.
• W3092571714 creator A5037600539 @default.
• W3092571714 creator A5038127187 @default.
• W3092571714 creator A5038699850 @default.
• W3092571714 creator A5044475225 @default.
• W3092571714 creator A5045065190 @default.
• W3092571714 creator A5045594197 @default.
• W3092571714 creator A5046165104 @default.
• W3092571714 creator A5046338076 @default.
• W3092571714 creator A5047235637 @default.
• W3092571714 creator A5048542701 @default.
• W3092571714 creator A5048651693 @default.
• W3092571714 creator A5048911959 @default.
• W3092571714 creator A5049484660 @default.
• W3092571714 creator A5051290699 @default.
• W3092571714 creator A5054630096 @default.
• W3092571714 creator A5055814473 @default.
• W3092571714 creator A5055839718 @default.
• W3092571714 creator A5056448859 @default.
• W3092571714 creator A5057103601 @default.
• W3092571714 creator A5057865348 @default.
• W3092571714 creator A5064081399 @default.
• W3092571714 creator A5069849677 @default.
• W3092571714 creator A5071729246 @default.
• W3092571714 creator A5073244507 @default.
• W3092571714 creator A5073455043 @default.
• W3092571714 creator A5073706004 @default.
• W3092571714 creator A5073765015 @default.
• W3092571714 creator A5074820920 @default.
• W3092571714 creator A5075990466 @default.
• W3092571714 creator A5076220229 @default.
• W3092571714 creator A5076676169 @default.
• W3092571714 creator A5076689640 @default.
• W3092571714 creator A5077237184 @default.
• W3092571714 creator A5079108130 @default.
• W3092571714 creator A5081834495 @default.
• W3092571714 creator A5083595044 @default.
• W3092571714 creator A5084488556 @default.
• W3092571714 creator A5086488055 @default.
• W3092571714 creator A5086664717 @default.
• W3092571714 creator A5088110010 @default.
• W3092571714 creator A5088697717 @default.
• W3092571714 creator A5088790730 @default.
• W3092571714 creator A5089065633 @default.
• W3092571714 creator A5090559000 @default.
• W3092571714 date "2020-10-01" @default.
• W3092571714 modified "2023-10-18" @default.
• W3092571714 title "Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI)" @default.
• W3092571714 cites W1888992399 @default.
• W3092571714 cites W2101099004 @default.
• W3092571714 cites W2106313387 @default.
• W3092571714 cites W2122779695 @default.
• W3092571714 cites W2126617656 @default.
• W3092571714 cites W2133116935 @default.
• W3092571714 cites W2140501627 @default.
• W3092571714 cites W2169387542 @default.
• W3092571714 cites W2169469834 @default.
• W3092571714 cites W2418068631 @default.
• W3092571714 cites W2427094903 @default.
• W3092571714 cites W2528981159 @default.
• W3092571714 cites W2558238271 @default.
• W3092571714 cites W2559492076 @default.
• W3092571714 cites W2584600732 @default.
• W3092571714 cites W2596877212 @default.
• W3092571714 cites W2609605008 @default.
• W3092571714 cites W2747484920 @default.
• W3092571714 cites W2748953078 @default.
• W3092571714 cites W2749557879 @default.
• W3092571714 cites W2754054868 @default.
• W3092571714 cites W2793448886 @default.
• W3092571714 cites W2887786226 @default.
• W3092571714 cites W2888292644 @default.
• W3092571714 cites W2892112375 @default.
• W3092571714 cites W2904505945 @default.
• W3092571714 cites W2904529981 @default.
• W3092571714 cites W2913641014 @default.
• W3092571714 cites W2933800222 @default.
• W3092571714 cites W2946079547 @default.
• W3092571714 cites W2951424940 @default.
• W3092571714 cites W2971165578 @default.
• W3092571714 cites W3023400402 @default.

• next